Sana Biotechnology reported that an investigational allogeneic cell therapy continued producing insulin in a single Type 1 diabetes patient at 14‑month follow‑up with no new safety signals. The update provides an early clinical signal of durable engraftment and function for an off‑the‑shelf cell‑based approach to insulin replacement. The result remains single‑patient and preliminary, but it informs dose, manufacturing and clinical development planning for Sana and competitors pursuing cell therapies for diabetes. Sponsors and investors will watch for corroborating data from additional patients and standardized measures of glycemic control, C‑peptide production, and immunologic safety before judging translational potential.